Table 1 Heart Failure Patient Characteristics
From: Transcriptional and free radical responses to LVAD therapy
Patients (n) | 14 |
Age (year) | 54.5 ± 14.63 |
Gender (% Male) | 78.5 |
Race (%Caucasian) | 100 |
Comorbid Illness (%) | DM 50% /HTN 100% /Afib 50%/CKD 57% |
LVEF at time of placement (%) | < 25 |
LVAD duration (Days) | 293.28 ± 212.51 |